Almac says its first leap into Next Generation Sequencing (NGS) data analysis services is a much needed-change from the industry’s current “one-size-fits-all” offering.
in-PharmaTechnologist presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Sirona, Hospira, and Biogen Idec.
HUYA Bioscience says it will strengthen bonds between Chinese drug innovators and worldwide developers and through its new partnership with the Tianjin Institute of Pharmaceutical Research (TIPR).
Danone and Mead Johnson may make a joint bid for the €8bn infant nutrition-dominated Pfizer nutrition business that is up for sale, according to press reports.
Outsourcing is a gamble for the industry that needs a closer collaborative approach if pharma firms want a successful performance, according to new research.
Quintiles has invested £3m ($4.6m) in a new UK-based biomarker R&D company in a continuation of its efforts to build in the field of personalised medicines.
in-PharmaTechnologist presents its weekly round-up of the latest career moves within the pharmaceutical industry, including news from Algeta, Pall and Octapharma.
inVentiv Health says it will now offer a one-stop-shop for pharma and biotech training services after merging its subsidiaries Pharmaceutical Institute and Preceptiv Learning Solutions.
Sigma-Aldrich says it is a step closer to becoming a one-stop-shop for biopharmas in the drug discovery process after it inked a takeover agreement with biological testing firm BioReliance.
Albany Molecular Research (AMRI) says ‘streamlining’ plan will focus on its drug licensing unit not its contract API research, development and manufacturing services division.
Further analysis is needed to assess the risk posed by low level pharmaceutical contamination of water supplies says the winner of Recipharm’s 2011 environmental award.
GSK CEO Andrew Witty has been knighted in the Queen's New Year Honours list in recognition of his services to the UK economy and pharmaceutical industry.
in-PharmaTechnologist presents its first weekly round-up of the new appointments in the industry of 2012, including news from Teva, Forma Therapeutics and Celgene.
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
Contract testing services supplier LabCorp has secured a credit facility with the Bank of America, citing capital expenditures and acquisitions among the potential uses of the funds.
Outsourcing-Pharma presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Patheon, Cetero and Roche.
Quintiles says its alliance with Intarcia Therapeutics – developer of an injection-free diabetes drug – uses a financing model that could replace “old-fashioned” outsourcing business relationships.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
in-PharmaTechnologist presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Vertex, Pfizer and Prolong.
LabCorp has finally been cleared to buy DNA testing services firm Orchid Cellmark after the US Federal Trade Commission (FTC) OKed the deal, albeit, with some conditions.
Quotient has stressed the importance of screening prototype formulations early in the development process to ensure efficient drug delivery in later phases.
